Metastatic Malignant Neoplasm in the Brain, Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer AJCC v7
Conditions
Brief summary
This randomized phase III trial is studying whole-brain radiation therapy and stereotactic radiosurgery with or without temozolomide or erlotinib to see how well they work compared to whole-brain radiation therapy and stereotactic radiosurgery in treating patients with brain metastases secondary to non-small cell lung cancer. Radiation therapy uses high-energy x-rays to kill tumor cells. Stereotactic radiosurgery may be able to deliver x-rays directly to the tumor and cause less damage to normal tissue. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop tumor cells from dividing so they stop growing or die. Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth and by blocking blood flow to the tumor. It is not yet known whether radiation therapy and stereotactic radiosurgery are more effective with or without temozolomide or erlotinib in treating brain metastases.
Detailed description
PRIMARY OBJECTIVES: I. Compare survival in patients with non-small cell lung cancer and brain metastases treated with whole brain radiotherapy and stereotactic radiosurgery with vs without temozolomide or erlotinib. SECONDARY OBJECTIVES: I. Compare time to CNS progression in patients treated with these regimens. II. Compare quality-adjusted survival in patients treated with these regimens. III. Compare 3-month quality of life in patients treated with these regimens. IV. Compare the 6-month performance status of patients treated with these regimens. V. Compare 6-month steroid dependence in patients treated with these regimens. VI. Compare cause of death (neurologic vs other) in patients treated with these regimens. VII. Determine the effects of non-protocol chemotherapy in these patients. OUTLINE: This is a randomized, multicenter study. Patients are stratified according to age and the presence of extracranial metastases (\< 65 years old AND no extracranial metastases vs ≥ 65 years old OR extracranial metastases), number of metastases (1 vs 2 or 3), and extent of extracranial disease (none vs present). Patients are randomized to 1 of 3 treatment arms. ARM I: Patients undergo whole brain radiotherapy (WBRT) once daily on days 1-5, 8-12, and 15-19. Within 14 days after completion of WBRT, patients undergo stereotactic radiosurgery. ARM II: Patients undergo WBRT and stereotactic radiosurgery as in arm I. Beginning on the first day of WBRT, patients receive oral temozolomide once daily on days 1-21. Beginning 4 weeks after completion of WBRT, patients may receive oral temozolomide alone once daily on days 1-5. Treatment with temozolomide repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. ARM III: Patients undergo WBRT and stereotactic radiosurgery as in arm I. Beginning on the first day of WBRT, patients receive oral erlotinib once daily for up to 6 months. In all arms, patients with recurrent brain metastases may undergo additional stereotactic radiosurgery. Quality of life is assessed at baseline and at 3, 6, 9, 12, 18, and 24 months. Patients are followed every 3 months for 2 years, every 6 months for 2 years, and then annually thereafter.
Interventions
RADIATION3-Dimensional Conformal Radiation Therapy
Patients undergo radiation therapy once daily for approximately 3 weeks
DRUGErlotinib Hydrochloride
Given orally
RADIATIONStereotactic Radiosurgery
Patients undergo surgery after radiation therapy
DRUGTemozolomide
Given orally
Sponsors
Radiation Therapy Oncology Group
National Cancer Institute (NCI)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically confirmed non-small cell lung cancer * One to 3 intraparenchymal brain metastases by contrast-enhanced MRI, meeting the following criteria: * Well circumscribed tumor(s) * Maximum diameter ≤ 4.0 cm * If multiple lesions are present and one lesion is at the maximum diameter, the other lesions must not exceed 3.0 cm in maximum diameter * No metastases within 10 mm of the optic apparatus such that a portion of the optic nerve or chiasm would be included in the high-dose stereotactic radiosurgery boost field * No metastases in the brainstem, midbrain, pons, or medulla * No prior complete resection of all known brain metastases * Subtotal resection allowed provided residual disease is ≤ 4.0 cm in maximum diameter * No clinical or radiographic evidence of progression (other than study lesion\[s\]) within the past month * Patients with brain metastases at initial presentation do not require 1 month of scans documenting stable disease * Stable extracranial metastases allowed * No known or pre-existing liver metastases * No leptomeningeal metastases by MRI or cerebrospinal fluid evaluation * Synchronous brain metastases at initial diagnosis allowed * Performance status - Zubrod 0-1 * Hemoglobin ≥ 8 g/dL * Absolute neutrophil count ≥ 1,000/mm\^3 * Platelet count ≥ 100,000/mm\^3 * AST \< 2 times upper limit of normal (ULN) * Alkaline phosphatase \< 2 times ULN unless due to elevated bone metastases * Total bilirubin normal * Lactic dehydrogenase \< 2 times ULN * Creatinine \< 1.5 times ULN * No clinically active interstitial lung disease * Chronic stable asymptomatic radiographic changes allowed * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * HIV negative * Neurologic function status 0-2 * No other major medical illness or psychiatric impairment that would preclude study participation * No history of allergic reaction attributed to compounds of similar chemical or biologic composition to erlotinib or temozolomide * No concurrent immunotherapy * No concurrent biologic therapy, excluding growth factors and epoetin alfa * No prior temozolomide or erlotinib * No other concurrent chemotherapy during study radiotherapy * Other concurrent chemotherapy allowed after study radiotherapy, except for the following: * Temozolomide or erlotinib (arm I only) * Erlotinib (arm II only) * Temozolomide (arm III only) * No prior cranial radiotherapy * No concurrent intensity-modulated radiotherapy * Concurrent radiotherapy to painful bone lesions allowed * No concurrent radiotherapy to more than 15% of bone marrow * No other concurrent therapy for brain metastases unless a recurrence is detected * More than 30 days since prior investigational drugs * No concurrent enzyme-inducing antiepileptic drugs including, but not limited to, any of the following (for patients randomized to receive erlotinib): * Phenytoin * Carbamazepine * Rifampin * Phenobarbital * Primidone * Oxcarbazepine * No other concurrent investigational drugs * No concurrent Hypericum perforatum (St. John's wort) * No drugs that alter gastric pH (e.g., proton pump inhibitors or H2 antagonists) within 4 hours after erlotinib administration (arm III patients only)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival | From randomization to date of death or last follow-up, up to 48.1 months. Analysis occurs after all patients have been potentially followed for 9 months. | Survival time is defined as time from randomization to date of death from any cause and estimated by the Kaplan-Meier method. Patients last known to be alive are censored at date of last contact. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Quality-adjusted Survival as Measured by EuroQol 5-dimension Instrument | From randomization to last follow-up, up to 48.1 months. Analysis occurs after all patients have been potentially followed for 9 months. | Quality-adjusted life years (QALY) incorporate the societal-based utilities of health states into expected life years for a health condition. The QALY model is QALY(h,y) where h is a health state and y is the years of life. Higher quality-adjusted life year values represent a better outcome. A patient's health state will be determined from the index score of the EQ-5D-5L patient questionnaire.The EQ-5D-5L is a 2-part self-assessment questionnaire, a 5-item index score and a visual analogue scale, but only the index score is used for quality-adjusted survival. The index score has 5 items (mobility, self care, usual activities, pain/discomfort, anxiety/depression) each with 5 problem levels (1-none to 5-extreme). The 5-item index score is transformed into a utility score between 0 (worst health state) and 1 (best health state). |
| Change in Functional Assessment of Cancer Therapy-Brain (FACT-Br) Score at 3 Months | From randomization to three months. | The Functional Assessment of Cancer Therapy-Brain (FACT-Br) is a 19-item self-report instrument designed to measure multidimensional quality of life in patients with brain cancer. It is to be administered with the FACT-General. There are 5 responses options, with 0=Not a lot and 4=Very much. All items are added together to obtain a total score, which ranges from 0 to 76. Certain items must be reversed before it is added by subtracting the response from 4. It requires at least 50% of the items to be completed while the overall response rate of the FACT-Br including the FACT-G must be greater than 80%. If items are missing, the subscale scores can be prorated. A higher score indicates better QOL. A change of 5 points will be considered a minimal clinically meaningful change. Change from baseline at three months (3 month score - baseline score) will be categorized as improvement if increased, stable if no change, or deterioration if decreased. |
| Rate of CNS Progression (One Year) | From randomization to last follow-up, up to 48.1 months. Analysis occurs after all patients have been potentially followed for 9 months. | CNS progression is defined as any increase in perpendicular bi-dimensional tumor area for any of the 1-3 tracked brain metastases, by any amount, or the appearance of any new brain metastasis on a follow-up MRI (SRS planning scan will not be used to evaluate CNS progression). For lesions smaller than 1 cm in maximum diameter, a maximum increase of 50% in perpendicular bi-dimensional treatment area is necessary to score as progression. This caveat is included to account for potential variability in measurement, which is most susceptible to proportionate errors at smaller sizes. For greater than 1 cm lesions, the definition uses a 25% rule for change. Rates of CNS progression estimated by the cumulative incidence method, with death treated as a competing risk. |
| Change in Steroid Dependence at Six Months | From randomization to six months. | Daily steroid dose will be collected at baseline and follow-up, as one of the following: 0-4 mg, \>4 to ≤ 8 mg, \>8 to ≤12 mg, and \>12 mg. Change from baseline at six months will be evaluated to have decreased, remained stable, or increased, based on these categories. |
| Cause of Death (Neurologic vs Other) | From randomization to last follow-up, up to 48.1 months. Analysis occurs after all patients have been potentially followed for 9 months. | Patients were considered to have died neurologic deaths (coded as Brain Metastases) if they had stable systemic disease and progressive neurologic disease consisting of expanding intracranial masses, CNS hemorrhages, hydrocephalus resulting in herniation or fulminant meningeal carcinomatosis. |
| Change in Performance Status at Six Months | From randomization to six months. | Compared between two treatment arms using a two-group chi-squared test. Zubrod score will be collected at baseline and follow-up. The Zubrod performance score runs from 0 to 5, with 0 denoting perfect health and 5 death. Change from baseline is calculated as 6-month value - baseline value. Patients with a baseline score who have died by six months will be included in the analysis with a score of 5 at six months. |
Countries
Canada, United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| WBRT + SRS Patients undergo whole brain radiotherapy (WBRT) once daily on days 1-5, 8-12, and 15-19. Within 14 days after completion of WBRT, patients undergo stereotactic radiosurgery. | 45 |
| Temozolomide + WBRT + SRS Patients undergo WBRT and stereotactic radiosurgery as in arm I. Beginning on the first day of WBRT, patients receive oral temozolomide once daily on days 1-21. Beginning 4 weeks after completion of WBRT, patients may receive oral temozolomide alone once daily on days 1-5. Treatment with temozolomide repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. | 40 |
| Erlotinib + WBRT + SRS Patients undergo WBRT and stereotactic radiosurgery as in arm I. Beginning on the first day of WBRT, patients receive oral erlotinib once daily for up to 6 months. | 41 |
| Total | 126 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Ineligible | 1 | 0 | 0 |
Baseline characteristics
| Characteristic | WBRT + SRS | Temozolomide + WBRT + SRS | Erlotinib + WBRT + SRS | Total |
|---|---|---|---|---|
| Age, Continuous | 63 years | 63 years | 61 years | 63 years |
| Sex: Female, Male Female | 22 Participants | 18 Participants | 18 Participants | 58 Participants |
| Sex: Female, Male Male | 23 Participants | 22 Participants | 23 Participants | 68 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — |
| other Total, other adverse events | 28 / 44 | 32 / 39 | 34 / 41 |
| serious Total, serious adverse events | 10 / 44 | 22 / 39 | 12 / 41 |
Outcome results
Primary
Overall Survival
Survival time is defined as time from randomization to date of death from any cause and estimated by the Kaplan-Meier method. Patients last known to be alive are censored at date of last contact.
Time frame: From randomization to date of death or last follow-up, up to 48.1 months. Analysis occurs after all patients have been potentially followed for 9 months.
Population: All eligible patients.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| WBRT + SRS | Overall Survival | 13.4 months |
| Temozolomide + WBRT + SRS | Overall Survival | 6.3 months |
| Erlotinib + WBRT + SRS | Overall Survival | 6.1 months |
Comparison: 120 patients per arm required to detect a 33% reduction in hazard rate corresponding to improvement in MST of 5.9 (null hypothesis) to 8.9 months with a one-sided type I error rate of 0.025 and 85% power.p-value: 0.9395% CI: [0.89, 2.31]Log Rank
Comparison: 120 patients per arm required to detect a 33% reduction in hazard rate corresponding to improvement in MST of 5.9 (null hypothesis) to 8.9 months with a one-sided type I error rate of 0.025 and 85% power.p-value: 0.9595% CI: [0.92, 2.36]Log Rank
Secondary
Cause of Death (Neurologic vs Other)
Patients were considered to have died neurologic deaths (coded as Brain Metastases) if they had stable systemic disease and progressive neurologic disease consisting of expanding intracranial masses, CNS hemorrhages, hydrocephalus resulting in herniation or fulminant meningeal carcinomatosis.
Time frame: From randomization to last follow-up, up to 48.1 months. Analysis occurs after all patients have been potentially followed for 9 months.
Population: Eligible patients who died
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| WBRT + SRS | Cause of Death (Neurologic vs Other) | Neuroligic death | 6 Participants |
| WBRT + SRS | Cause of Death (Neurologic vs Other) | Other | 29 Participants |
| Temozolomide + WBRT + SRS | Cause of Death (Neurologic vs Other) | Neuroligic death | 5 Participants |
| Temozolomide + WBRT + SRS | Cause of Death (Neurologic vs Other) | Other | 29 Participants |
| Erlotinib + WBRT + SRS | Cause of Death (Neurologic vs Other) | Neuroligic death | 7 Participants |
| Erlotinib + WBRT + SRS | Cause of Death (Neurologic vs Other) | Other | 29 Participants |
Comparison: A two group chi-square test with a 0.05 two-sided significance level would have 89% power to detect the difference between a proportion of 0.50 and a proportion of 0.30, or equivalently, of 0.70, when the sample size in each group is 120.p-value: 0.78Chi-squared
Comparison: A two group chi-square test with a 0.05 two-sided significance level would have 89% power to detect the difference between a proportion of 0.50 and a proportion of 0.30, or equivalently, of 0.70, when the sample size in each group is 120.p-value: 0.8Chi-squared
Secondary
Change in Functional Assessment of Cancer Therapy-Brain (FACT-Br) Score at 3 Months
The Functional Assessment of Cancer Therapy-Brain (FACT-Br) is a 19-item self-report instrument designed to measure multidimensional quality of life in patients with brain cancer. It is to be administered with the FACT-General. There are 5 responses options, with 0=Not a lot and 4=Very much. All items are added together to obtain a total score, which ranges from 0 to 76. Certain items must be reversed before it is added by subtracting the response from 4. It requires at least 50% of the items to be completed while the overall response rate of the FACT-Br including the FACT-G must be greater than 80%. If items are missing, the subscale scores can be prorated. A higher score indicates better QOL. A change of 5 points will be considered a minimal clinically meaningful change. Change from baseline at three months (3 month score - baseline score) will be categorized as improvement if increased, stable if no change, or deterioration if decreased.
Time frame: From randomization to three months.
Population: Eligible patients with both baseline and 3 month data
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| WBRT + SRS | Change in Functional Assessment of Cancer Therapy-Brain (FACT-Br) Score at 3 Months | Deterioration/Decrease | 12 Participants |
| WBRT + SRS | Change in Functional Assessment of Cancer Therapy-Brain (FACT-Br) Score at 3 Months | Improvement/Increase | 6 Participants |
| WBRT + SRS | Change in Functional Assessment of Cancer Therapy-Brain (FACT-Br) Score at 3 Months | Stable | 8 Participants |
| Temozolomide + WBRT + SRS | Change in Functional Assessment of Cancer Therapy-Brain (FACT-Br) Score at 3 Months | Deterioration/Decrease | 10 Participants |
| Temozolomide + WBRT + SRS | Change in Functional Assessment of Cancer Therapy-Brain (FACT-Br) Score at 3 Months | Stable | 2 Participants |
| Temozolomide + WBRT + SRS | Change in Functional Assessment of Cancer Therapy-Brain (FACT-Br) Score at 3 Months | Improvement/Increase | 4 Participants |
| Erlotinib + WBRT + SRS | Change in Functional Assessment of Cancer Therapy-Brain (FACT-Br) Score at 3 Months | Deterioration/Decrease | 11 Participants |
| Erlotinib + WBRT + SRS | Change in Functional Assessment of Cancer Therapy-Brain (FACT-Br) Score at 3 Months | Improvement/Increase | 1 Participants |
| Erlotinib + WBRT + SRS | Change in Functional Assessment of Cancer Therapy-Brain (FACT-Br) Score at 3 Months | Stable | 6 Participants |
Comparison: With 70 patients per arm, a 0.05 level chi-square test would have 80% power to distinguish between two groups when the proportions in the three categories are as follows for standard vs. experimental arm, respectively: 25% vs. 50% improvement, 55% vs. 40% stable, and 20% vs. 10% deterioration, or any distribution that corresponds to an effect size, Δ² = Σ(π2j-π1j)2/\[2(π2j-π1j)\], of 0.0702.p-value: 0.39Chi-squared
Comparison: With 70 patients per arm, a 0.05 level chi-square test would have 80% power to distinguish between two groups when the proportions in the three categories are as follows for standard vs. experimental arm, respectively: 25% vs. 50% improvement, 55% vs. 40% stable, and 20% vs. 10% deterioration, or any distribution that corresponds to an effect size, Δ² = Σ(π2j-π1j)2/\[2(π2j-π1j)\], of 0.0702.p-value: 0.28Chi-squared
Secondary
Change in Performance Status at Six Months
Compared between two treatment arms using a two-group chi-squared test. Zubrod score will be collected at baseline and follow-up. The Zubrod performance score runs from 0 to 5, with 0 denoting perfect health and 5 death. Change from baseline is calculated as 6-month value - baseline value. Patients with a baseline score who have died by six months will be included in the analysis with a score of 5 at six months.
Time frame: From randomization to six months.
Population: Eligible patients with baseline and 6 month data
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| WBRT + SRS | Change in Performance Status at Six Months | Stable (no change) | 19 Participants |
| WBRT + SRS | Change in Performance Status at Six Months | Improvement (decrease) | 0 Participants |
| WBRT + SRS | Change in Performance Status at Six Months | Deterioration (increase) | 21 Participants |
| Temozolomide + WBRT + SRS | Change in Performance Status at Six Months | Stable (no change) | 4 Participants |
| Temozolomide + WBRT + SRS | Change in Performance Status at Six Months | Improvement (decrease) | 1 Participants |
| Temozolomide + WBRT + SRS | Change in Performance Status at Six Months | Deterioration (increase) | 30 Participants |
| Erlotinib + WBRT + SRS | Change in Performance Status at Six Months | Improvement (decrease) | 3 Participants |
| Erlotinib + WBRT + SRS | Change in Performance Status at Six Months | Deterioration (increase) | 30 Participants |
| Erlotinib + WBRT + SRS | Change in Performance Status at Six Months | Stable (no change) | 2 Participants |
Comparison: 108 with three month performance status data, per arm, would result in a 0.050 level chi-square test with 90% power to distinguish between the groups when the proportions in the 3 categories are characterized by an effect size, Δ² = Σ(π2j-π1j)2/\[2(π2j-π1j)\], of 0.0586.p-value: 0.002Chi-squared
Comparison: 108 cases with three month performance status data, per arm, would result in a 0.050 level chi-square test with 90% power to distinguish between the groups when the proportions in the 3 categories are characterized by an effect size, Δ² = Σ(π2j-π1j)2/\[2(π2j-π1j)\], of 0.0586.p-value: <0.001Chi-squared
Secondary
Change in Steroid Dependence at Six Months
Daily steroid dose will be collected at baseline and follow-up, as one of the following: 0-4 mg, \>4 to ≤ 8 mg, \>8 to ≤12 mg, and \>12 mg. Change from baseline at six months will be evaluated to have decreased, remained stable, or increased, based on these categories.
Time frame: From randomization to six months.
Population: Eligible patients with both baseline and 6 month steroid dose
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| WBRT + SRS | Change in Steroid Dependence at Six Months | Stable | 10 Participants |
| WBRT + SRS | Change in Steroid Dependence at Six Months | Decrease | 12 Participants |
| WBRT + SRS | Change in Steroid Dependence at Six Months | Increase | 4 Participants |
| Temozolomide + WBRT + SRS | Change in Steroid Dependence at Six Months | Stable | 4 Participants |
| Temozolomide + WBRT + SRS | Change in Steroid Dependence at Six Months | Decrease | 10 Participants |
| Temozolomide + WBRT + SRS | Change in Steroid Dependence at Six Months | Increase | 4 Participants |
| Erlotinib + WBRT + SRS | Change in Steroid Dependence at Six Months | Decrease | 10 Participants |
| Erlotinib + WBRT + SRS | Change in Steroid Dependence at Six Months | Increase | 1 Participants |
| Erlotinib + WBRT + SRS | Change in Steroid Dependence at Six Months | Stable | 6 Participants |
p-value: 0.51Chi-squared
Comparison: Assuming the survival rate of the standard arm (MST = 5.9 months), then 49% of patients were expected to be alive at six months. Assuming steroid data would be available for 90% of these patients, results in a projection of 52 cases/arm with steroid data at 6 months. With this sample size, a two-sided 0.050 alpha test will have 90% power to distinguish between the groups when the proportions in the 3 categories are characterized by an effect size, Δ² = Σ(π2j-π1j)2/\[2(π2j-π1j)\], of 0.1217.p-value: 0.56Chi-squared
Secondary
Quality-adjusted Survival as Measured by EuroQol 5-dimension Instrument
Quality-adjusted life years (QALY) incorporate the societal-based utilities of health states into expected life years for a health condition. The QALY model is QALY(h,y) where h is a health state and y is the years of life. Higher quality-adjusted life year values represent a better outcome. A patient's health state will be determined from the index score of the EQ-5D-5L patient questionnaire.The EQ-5D-5L is a 2-part self-assessment questionnaire, a 5-item index score and a visual analogue scale, but only the index score is used for quality-adjusted survival. The index score has 5 items (mobility, self care, usual activities, pain/discomfort, anxiety/depression) each with 5 problem levels (1-none to 5-extreme). The 5-item index score is transformed into a utility score between 0 (worst health state) and 1 (best health state).
Time frame: From randomization to last follow-up, up to 48.1 months. Analysis occurs after all patients have been potentially followed for 9 months.
Population: Eligible patients with any follow-up EQ-5D
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| WBRT + SRS | Quality-adjusted Survival as Measured by EuroQol 5-dimension Instrument | 16.9 Quality-adjusted life years | Standard Deviation 9.6 |
| Temozolomide + WBRT + SRS | Quality-adjusted Survival as Measured by EuroQol 5-dimension Instrument | 15.9 Quality-adjusted life years | Standard Deviation 12 |
| Erlotinib + WBRT + SRS | Quality-adjusted Survival as Measured by EuroQol 5-dimension Instrument | 14.4 Quality-adjusted life years | Standard Deviation 12.5 |
Secondary
Rate of CNS Progression (One Year)
CNS progression is defined as any increase in perpendicular bi-dimensional tumor area for any of the 1-3 tracked brain metastases, by any amount, or the appearance of any new brain metastasis on a follow-up MRI (SRS planning scan will not be used to evaluate CNS progression). For lesions smaller than 1 cm in maximum diameter, a maximum increase of 50% in perpendicular bi-dimensional treatment area is necessary to score as progression. This caveat is included to account for potential variability in measurement, which is most susceptible to proportionate errors at smaller sizes. For greater than 1 cm lesions, the definition uses a 25% rule for change. Rates of CNS progression estimated by the cumulative incidence method, with death treated as a competing risk.
Time frame: From randomization to last follow-up, up to 48.1 months. Analysis occurs after all patients have been potentially followed for 9 months.
Population: Eligible patients
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| WBRT + SRS | Rate of CNS Progression (One Year) | 34.1 percentage of participants |
| Temozolomide + WBRT + SRS | Rate of CNS Progression (One Year) | 47.4 percentage of participants |
| Erlotinib + WBRT + SRS | Rate of CNS Progression (One Year) | 27.4 percentage of participants |
p-value: 0.3Gray's test
p-value: 0.48Gray's test